Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of EE/Norgestimate on Lomitapide PK in Healthy Females
NCT02080468Phase 1Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lomitapide in homozygous familial hypercholesterolemia (HoFH) (2 arms), sponsored by Aegerion Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) for Lomitapide at 169 hours, Time to Maximum Plasma Concentration (Tmax) for Lomitapide at 169 hours and 3 more. Started Feb 2014; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02080468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080468.